Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 5/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 1/20 | 0.39 |
| ▸ | CD69 | Q07108 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.39 |
| ▸ | CDKL2 | Q92772 | 1/20 | 0.39 |
| ▸ | RIOK1 | Q9BRS2 | 1/20 | 0.39 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.39 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16793564 | 0.80 | BTK (0.53) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL16793852 | 0.75 | BTK (0.47) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL20027005 | 0.73 | BTK (0.41) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL16793935 | 0.72 | BTK (0.47) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL18183911 | 0.70 | BTK (0.48) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL20027003 | 0.69 | BTK (0.45) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL25590604 | 0.68 | BTK (0.53) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL18179518 | 0.64 | BTK (0.53) | BTKEPHX2 | |
| SCHEMBL25584965 | 0.63 | BTK (0.59) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL20461055 | 0.62 | BTK (0.61) | BTKJAK2CYP3A4HRH2CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10280169-B2 | Biaryl bruton's tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2019-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280169-B2 | Biaryl bruton's tyrosine kinase inhibitors | ABL1, BTK, LYN | BTK 2/4885JAK2 20/4885CYP3A4 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.